Alerta

CONJUGATED POLYETHYLENEIMINE COMPOUNDS AND COMPOSITIONS, AND USES THEREOF FOR THE TREATMENT OF ATHEROSCLEROSIS, CARDIOVASCULAR, AND LUNG DISEASE

Resumen de: WO2024220742A1

Provided herein are lipid conjugated polyethyleneimine (PEI) compounds of Formula (I), which are useful to form delivery systems, such as lipid nanoparticles, for delivery of agents (e.g., nucleic acid molecules) to cells (e.g., endothelial cells). Also provided herein are methods for treating atherosclerosis, a cardiovascular disease, a pulmonary hypertension (e.g, pulmonary arterial hypertension or secondary pulmonary hypertension), a lung cancer, a lung metastasis, chronic obstructive pulmonary disease (COPD), bronchiolitis obliterans, bronchiolitis obliterans organizing pneumonia (BOOP), pulmonary fibrosis, or a fibrotic lung disease, comprising administering to a subject a pharmaceutical composition comprising lipid conjugated polyethyleneimine (PEI) compounds of Formula (I), an agent, and a pharmaceutically acceptable excipient.

LIPID NANOPARTICLE (LNP) DELIVERY SYSTEMS AND FORMULATIONS

Resumen de: MX2025012462A

The present disclosure describes compositions, nanoparticles (such as lipid nanoparticles), and/or lipid nanoparticle compositions and methods of their use.

DELIVERY OF NUCLEIC ACIDS USING A TARGETED PEPTIDE CARRIER SYSTEM

Resumen de: WO2024220878A1

A layer-by-layer ELP-nucleic acid (NA) nanoparticle (LENN) complex for targeted delivery of a therapeutic NA cargo to tumor cells; a method of formulating a LENN complex using a layer-by-layer deposition process (LbL); LENN complex formulations; pharmaceutical compositions comprising a LENN complex formulations; and methods of treating bladder cancer in a subject via LENN-mediated delivery of a therapeutic NA cargo.

VACCINE COMPOSITIONS AND USES THEREOF

Resumen de: WO2024220936A1

The present disclosure provides vaccine compositions comprising a plurality of distinct antigens. Also provided are nucleic acid vaccine composition comprising one or more nucleic acids encoding for a plurality of distinct antigens. The plurality of distinct antigens comprises a combination of influenza antigens. The vaccine composition can be formulated for delivery as a mRNA/LNP, a recombinant protein, a virus-like particle (VLP), or DNA. Methods of preventing an influenza infection and methods of inducing an immune response are also disclosed.

TIMESCALE-GUIDED MICROFLUIDIC SYNTHESIS OF POLYPHENOL-IRON III NETWORK NANOCAPSULES OF HYDROPHOBIC DRUGS

Resumen de: WO2024220674A1

A scalable method of continuous microfluidic synthesis of tannic acid-iron III (TA-FeIII) network (TFN) nanocapsules of a hydrophobic drug; a scalable method of continuous microfluidic synthesis of epigallocatechin-3-gallate iron III (EGCG-FeIII) network, (EFN) nanocapsules; hydrophobic drug nanocapsules synthesized in accordance with the method; and a method of administering a hydrophobic drug to a patient in need thereof by administering to the patient the hydrophobic drug nanocapsules.

DELIVERY OF POLYNUCLEOTIDES FROM LIPID NANOPARTICLES COMPRISING RNA AND IONIZABLE LIPIDS

Resumen de: WO2024220625A1

Provided herein is a method for delivering an RNA composition to a subject for in vivo production of a protein or a peptide in the subject, comprising administering to the subject an RNA composition comprising a polynucleotide that encodes a protein or a peptide, formulated within (a) a plurality of lipid nanoparticles (LNP) comprising synthetic structural lipids and an ionizable lipid, or (b) a lipid reconstructed natural messenger packs (LNMPs) comprising natural lipids and an ionizable lipid. Also provided herein are methods for treating diseases or disorders associated with the gastrointestinal tract, stomach, small or large intestine, mesenteric lymph node, pancreas, colon or rectum, caecum, and/or spleen, comprising orally or enterally administering the RNA composition described herein.

RECONSTITUTABLE DRY POWDER FORMULATIONS AND METHODS OF USE THEREOF

Resumen de: MX2025012337A

The present disclosure is directed to the use of reconstituted mRNA dry powder particles for parenteral administration. The present disclosure is also directed to a method of generating dry powder particles supplemented with appropriate excipients for optimal thermostability and in vivo expression.

CAPSID VARIANTS AND USES THEREOF

Resumen de: US2025319207A1

Aspects of the disclosure relate to compositions and methods for delivering a transgene (e.g., a transgene encoding one or more gene products) to a target cell (e.g., an ocular cell). The disclosure is based, in part, on adeno-associated virus (AAV) capsid protein variants and methods of using same for delivery of a transgene.

FLUORINATED CATIONIC LIPIDS FOR USE IN LIPID NANOPARTICLES

Resumen de: EP4700017A2

Compounds are provided having the following structure:or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein R^2a, R^2b, R^3a, R^3b, R⁷, R⁸, R⁹, L¹, L², G¹, G², G³, b, and c are as defined herein. Use of the compounds as a component of lipid nanoparticle formulations for delivery of a therapeutic agent, compositions comprising the compounds and methods for their use and preparation are also provided.

用于转运具有阴离子基团的活性物质的纳米颗粒、其制备方法及其用途

Resumen de: WO2024235481A1

The invention relates to lipid nanoparticles containing selected quantities of a) at least one cationic lipid, b) at least one phospholipid, and c) at least one selected stealth lipid, with the proviso that all the lipids contained in the lipid nanoparticle have an HLB value of greater than or equal to 3. These nanoparticles can be charged with active substances containing anionic groups, preferably with nucleic acids, and are suitable as highly efficient vehicles for transferring nucleic acids into cells.

具有侧挂阳离子基团的聚(噁唑啉)缀合物及包含其的脂质纳米粒和多聚复合物

Resumen de: AU2024304918A1

Poly(oxazoline) conjugates with pendant cationic groups (cationic POZ) and lipid nanoparticles (LNPs) including cationic POZ used to facilitate delivery of an encapsulated payload. LNPs and polyplexes including cationic POZ and a nucleic acid payload such as, but not limited to, mRNA or modified mRNA are disclosed. Such LNPs have no immunogenicity or reduced immunogenicity as compared to a corresponding LNP containing an ionizable lipid.

具有芳香族头基团的基于三(羟甲基)甲基甘氨酸和柠檬酸的阳离子脂质

Resumen de: WO2024256457A1

The present invention provides, in part, tricene and citric acid-based cationic lipids with aromatic head groups of Formula (I), and sub-formulas thereof: or a pharmaceutically acceptable salt thereof. The compounds provided herein can be useful for delivery and expression of mRNA and encoded protein, e.g., as a component of liposomal delivery vehicle, and accordingly can be useful for treating various diseases, disorders and conditions, such as those associated with deficiency of one or more proteins.

一种吉西他滨纳米颗粒、抗肿瘤联合用药物及应用

Resumen de: CN121550178A

本发明涉及生物制药技术领域，具体涉及一种吉西他滨纳米颗粒、抗肿瘤联合用药物及应用，所述吉西他滨纳米颗粒由吉西他滨内核和包覆其外的细胞膜组成；所述细胞膜来源于经基因工程改造后过表达PD‑1的CT26‑PD‑1细胞；所述吉西他滨纳米颗粒粒径大小为150nm~200nm。本发明通过过表达PD‑1的肿瘤细胞膜包覆吉西他滨，借助PD‑1和PD‑L1的相互作用增强了吉西他滨在肿瘤中富集的能力，改善了吉西他滨的生物毒性和较短的血液半衰期；并通过联合CD73抑制剂AB680实现对结直肠癌的精准靶向递送和免疫微环境调控，为肿瘤治疗提供了一种高效、低毒的创新方案。

可电离胺脂质

Resumen de: AU2024275548A1

The disclosure provides ionizable lipids and lipid nanoparticle (LNP) compositions comprising ionizable lipids, helper lipids, neutral lipids, and PEG lipids useful for the delivery of biologically active agents, for example delivering biologically active agents to cells to prepare engineered cells. The LNP compositions disclosed herein are useful in methods of gene editing and methods of delivering a biologically active agent and methods of modifying or cleaving DNA.

一种用于梅毒光驱动治疗的多功能仿生纳米粒子及其制备方法和应用

Resumen de: CN121550423A

本发明公开了一种用于梅毒光驱动治疗的多功能仿生纳米粒子及其制备方法和应用。所述多功能仿生纳米粒子为外膜包覆核心的结构，所述外膜为被梅毒螺旋体预先激活的巨噬细胞的细胞膜，所述核心为具有AIE型光敏剂复合材料。本发明提供的多功能仿生纳米粒子可实现梅毒硬下疳和硬下疳内病原体的分级靶向，表现出对皮疹的精确跟踪和近红外区I区荧光成像；在808nm激光照射下，多功能仿生纳米粒子产生高效的光热和光动力效应，梅毒螺旋体可以被光裂解消除，从而实现梅毒的无创光疗。该多功能仿生纳米粒子不仅可以作为仿生纳米药物用于梅毒的靶向治疗，降低药物的毒副作用，还可以同时实现高分辨率成像，达到多模态综合诊疗的目的。

用于皮肤疾病局部治疗的脂质纳米颗粒组合物

Resumen de: WO2025021083A1

Provided herein is a lipid nanoparticle (LNP) composition for the localized treatment of skin diseases and a method of treating skin diseases with the LNP composition.

一种基于中药活性成分的肾癌靶向纳米片剂及其制备方法

Resumen de: CN121550391A

本发明公开了一种基于中药活性成分的肾癌靶向纳米片剂及其制备方法，其特征在于：包括补益脾肾组分、滋阴潜阳组分、活血化瘀组分、清热解毒组分和温阳化气组分，通过对原料预处理，收集各药材的提取物；活性成分纳米化，获得粒径均匀的纳米粒混悬液；靶向配体修饰，获得功能化纳米粒混悬液；以微晶纤维素为骨架材料，羟丙基甲基纤维素为粘合剂，采用直接压片法制备片芯；采用高效包衣锅进行三层包衣；质量检测与包装，确保产品稳定性和用药安全。本发明兼具传统中药多靶点作用和现代纳米技术靶向递送优势的肾癌治疗纳米片剂，通过特殊辅料与引经药构建靶向通路，提高药物在肾癌组织的富集，增强治疗效果。

一种具有超氧化物歧化酶活性的铜离子/没食子酸纳米酶及其制备方法与应用

Resumen de: CN121550253A

本发明涉及一种具有超氧化物歧化酶活性的铜离子/没食子酸纳米酶及其制备方法与应用。该纳米酶由铜离子、没食子酸与氢氧化钠在去离子水中反应形成，反应在约30℃的水浴条件下进行1至3小时，所得纳米酶经离心富集获得。所述铜离子、没食子酸与氢氧化钠的摩尔投料比为1:1:0.5至1:1:2，铜源可选用三水合硝酸铜或二水合氯化铜。本发明纳米酶具有良好的分散性和稳定性，表现出优异的超氧阴离子清除能力，模拟天然超氧化物歧化酶活性，适用于制备治疗氧化应激相关疾病的药物，特别是在炎症性疾病、心脑血管疾病及神经退行性疾病等领域具有广阔的应用前景。

一种纳米中药灵芝保健品固体饮料及其制备方法

Resumen de: CN121549483A

本发明涉及保健品领域，具体涉及一种纳米中药灵芝保健品固体饮料及其制备方法，该固体饮料主要由纳米灵芝提取物、低聚果糖、木糖醇、抗性糊精、柠檬酸、苹果酸、天然香料及甜味剂组成。其制备方法包括灵芝预处理、纳米处理、提取、浓缩、调配、干燥和包装步骤。本发明通过纳米研磨技术将灵芝粉碎成纳米级粉末，增加了灵芝与溶剂的接触面积，结合超声辅助提取、微波辅助提取或酶解辅助提取等技术，可显著提高灵芝有效成分的提取率。同时，纳米级灵芝粉末和能量植入使灵芝分子的活性和能量状态发生改变，更易于被人体吸收，提高了生物利用度。

一种双蛋白微胶囊及其应用

Resumen de: CN121550185A

本发明公开了一种双蛋白微胶囊及其应用，该微胶囊由乳铁蛋白分别与α‑乳白蛋白、β‑乳球蛋白或酪蛋白形成的双蛋白复合物，结合海藻酸钠经内源乳化法包封益生菌制得。其核心优势在于双蛋白复合物通过空间屏障作用增强胃酸耐受性，益生元效应协同海藻酸钠的控释特性，大幅提升益生菌肠道活性保留与靶向释放效率；“物理保护‑营养协同”双重机制赋予微胶囊28天优异贮藏稳定性。本发明将双蛋白特异性相互作用与多糖包封技术结合，提供了可复制的优化参数与理论依据，有效解决益生菌递送中“活性‑释放‑贮藏”协同难题，为合生元微胶囊精准设计提供参考。

一种铑纳米酶复合物及其在制备预防、缓解和/或治疗药物性肝损伤的药物中的应用

Resumen de: CN121550183A

本申请涉及一种铑纳米酶复合物及其在制备预防、缓解和/或治疗药物性肝损伤的药物中的应用，其包括细胞外囊泡模拟物以及位于所述细胞外囊泡模拟物内的铑纳米酶。铑纳米酶表面包覆有细胞外囊泡模拟物，细胞外囊泡模拟物具有良好的生物相容性、低免疫原性，并能促进组织修复与再生，细胞外囊泡模拟物会被非特异性地清除，进而靶向富集在肝脏，这使得铑纳米酶一起被富集在肝脏，而铑纳米酶具有优异的超氧化物歧化酶SOD和过氧化氢酶CAT模拟活性，能高效清除多种活性氧物种，可以抑制APAP引发的炎症反应，从而对药物性肝损伤具有靶向治疗效果。

一种结核分枝杆菌mRNA疫苗及其构建方法与应用

Resumen de: CN121554604A

本发明名称为一种结核分枝杆菌mRNA疫苗及其构建方法与应用，属于生物医药技术领域。所要解决的技术问题为提供一种剂量低、安全性高、免疫记忆持久的新型结核分枝杆菌mRNA疫苗。技术方案要点为将编码Hsp65和Mpt83抗原串联表达，结合tPA信号肽（SEQ ID NO:1）、MITD序列（SEQ ID NO:5）及柔性Linker（SEQ ID NO:6‑7）构建mRNA分子，再通过密码子优化（mRNA二级结构、GC含量）和脂质纳米颗粒（LNP）包封工艺，最终获得一种新型结核分枝杆菌mRNA疫苗。

透明质酸钠-地塞米松纳米颗粒、其制备方法及应用

Resumen de: CN121550179A

本发明涉及药物制剂技术领域，提供一种透明质酸钠‑地塞米松纳米颗粒、其制备方法及应用。该方法中，将地塞米松溶解于乙醇得到地塞米松‑乙醇溶液，将透明质酸钠溶解于水性溶剂得到透明质酸钠水溶液，并对透明质酸钠水溶液预热；随后采用微流控合成装置，将地塞米松‑乙醇溶液作为脂相、预热后的透明质酸钠水溶液作为水相，以设定的总流速及脂相与水相流速比同步注入微流控混合通道，在通道内原位形成透明质酸钠‑地塞米松纳米颗粒分散液，并进行固化处理，必要时进一步分散于磷酸盐缓冲液中。所得纳米颗粒具有粒径小、分散性好、稳定性高和便于表面修饰等优点，可用于制备用于预防或治疗炎症性疾病的药物。

一种ROS响应型脂质体复合材料及其制备方法与应用

Resumen de: CN121550176A

本发明属于生物医药技术领域，更具体地，涉及一种ROS响应型脂质体复合材料及其制备方法与应用，所述ROS响应型脂质体复合材料是将紫草素和瑞舒伐他汀共同负载到含有ROS敏感性连接物DSPE‑TK‑PEG2000修饰的脂质体上，进一步将仿生膜包裹在外层，即得所述ROS响应型脂质体复合材料。本发明利用ROS响应的设计特点，实现药物在病变部位的特异性聚集和响应型释放，并有效延长药物的血液循环半衰期，结合紫草素和瑞舒伐他汀两种不同机理的抗动脉粥样硬化效应，达到有效治疗同型半胱氨酸诱导的动脉粥样硬化的效果。

一种斑蝥素智能药物递送系统

Nº publicación: CN121550184A 24/02/2026

Solicitante:

内蒙古医科大学

Resumen de: CN121550184A

本发明属于生物医药技术领域，涉及一种斑蝥素智能药物递送系统。本发明通过一种具有精确pH响应功能的聚合物杂化载体来递送斑蝥素，实现了斑蝥素的高效递送并显著改善了斑蝥素的组织分布与释药性能，特别是该体系可以具有良好的溶酶体逃逸功能，显著提升了斑蝥素抗乳腺癌的疗效与安全性。